Bonus Biogroup Stock Cash And Equivalents
| BONS Stock | ILS 10.80 0.10 0.93% |
Bonus Biogroup fundamentals help investors to digest information that contributes to Bonus Biogroup's financial success or failures. It also enables traders to predict the movement of Bonus Stock. The fundamental analysis module provides a way to measure Bonus Biogroup's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bonus Biogroup stock.
Bonus |
Bonus Biogroup Company Cash And Equivalents Analysis
Bonus Biogroup's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Bonus Biogroup Cash And Equivalents | 3.6 M |
Most of Bonus Biogroup's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bonus Biogroup is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Bonus Biogroup has 3.6 M in Cash And Equivalents. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The cash and equivalents for all Israel stocks is notably lower than that of the firm.
Bonus Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bonus Biogroup's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bonus Biogroup could also be used in its relative valuation, which is a method of valuing Bonus Biogroup by comparing valuation metrics of similar companies.Bonus Biogroup is currently under evaluation in cash and equivalents category among its peers.
Bonus Fundamentals
| Return On Equity | -0.55 | |||
| Return On Asset | -0.0636 | |||
| Current Valuation | 169.66 M | |||
| Shares Outstanding | 1.17 B | |||
| Shares Owned By Insiders | 49.72 % | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Book | 3.39 X | |||
| EBITDA | (88.03 M) | |||
| Net Income | (90.08 M) | |||
| Cash And Equivalents | 3.6 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 6.28 M | |||
| Current Ratio | 0.35 X | |||
| Book Value Per Share | 0.12 X | |||
| Cash Flow From Operations | (39.84 M) | |||
| Earnings Per Share | (0.08) X | |||
| Number Of Employees | 13 | |||
| Beta | 1.4 | |||
| Market Capitalization | 223.15 M | |||
| Total Asset | 104.32 M | |||
| Z Score | 21.0 | |||
| Net Asset | 104.32 M |
About Bonus Biogroup Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bonus Biogroup's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bonus Biogroup using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bonus Biogroup based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Bonus Stock
Bonus Biogroup financial ratios help investors to determine whether Bonus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bonus with respect to the benefits of owning Bonus Biogroup security.